NewsNTech
For a small European biotech, the U.S. commercial launch decision is a capital problem before it is a strategy problem.
Building a domestic sales force and carrying the operating burn until revenue materializes both precede the first substantial return, and a company that cannot self-fund those years typically faces a binary choice: find a U.S.
partner to share the commercial risk, or sell to a buyer who can absorb it. Abivax has now raised $920 million, and its CEO told CNBC that cash gives the French biotech the ability to pursue a solo U.S.
launch rather than depending on finding a buyer. What the runway number actually buys The latest fundraising round gives Abivax cash to finance operations through 2029. That date is the operative fact.
Keep reading